Real-life Effectiveness of Afatinib
Adult
Afatinib
/ therapeutic use
Aged
Aged, 80 and over
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Czech Republic
/ epidemiology
Disease Progression
ErbB Receptors
/ genetics
Female
Gefitinib
/ therapeutic use
Humans
Lung Neoplasms
/ drug therapy
Male
Middle Aged
Mutation
Retrospective Studies
Treatment Outcome
Young Adult
Afatinib
NSCLC
gefitinib
real world data
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
30
01
2021
revised:
17
02
2021
accepted:
18
02
2021
entrez:
4
4
2021
pubmed:
5
4
2021
medline:
28
4
2021
Statut:
ppublish
Résumé
We investigated efficacy differences for afatinib versus gefitinib in non-small-cell lung cancer (NSCLC) according to epidermal growth factor receptor (EGFR) mutations. We retrospectively analysed data for 343 patients with NSCLC with performance status 1 having EGFR mutations treated with gefitinib or afatinib. Overall response rate (ORR) was tested by Fisher's exact test. Overall (OS) and progression-free (PFS) survival were estimated by Kaplan-Meier method. ORR did not differ in any group or subgroup. Among all patients, we observed significantly longer PFS for those treated with afatinib vs. gefitinib (median 13.4 vs. 9.5 months, p=0.026), but only a nonsignificant trend was observed for OS. We showed nonsignificant trends of better PFS and OS using afatinib for exon 19 deletion and L858R subgroups. We observed no significant PFS differences for other EGFR mutations but a nonsignificant trend towards better OS for those treated with afatinib. Afatinib led to longer PFS for patients with common EGFR mutations but not for those with rare mutations.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
We investigated efficacy differences for afatinib versus gefitinib in non-small-cell lung cancer (NSCLC) according to epidermal growth factor receptor (EGFR) mutations.
PATIENTS AND METHODS
METHODS
We retrospectively analysed data for 343 patients with NSCLC with performance status 1 having EGFR mutations treated with gefitinib or afatinib. Overall response rate (ORR) was tested by Fisher's exact test. Overall (OS) and progression-free (PFS) survival were estimated by Kaplan-Meier method.
RESULTS
RESULTS
ORR did not differ in any group or subgroup. Among all patients, we observed significantly longer PFS for those treated with afatinib vs. gefitinib (median 13.4 vs. 9.5 months, p=0.026), but only a nonsignificant trend was observed for OS. We showed nonsignificant trends of better PFS and OS using afatinib for exon 19 deletion and L858R subgroups. We observed no significant PFS differences for other EGFR mutations but a nonsignificant trend towards better OS for those treated with afatinib.
CONCLUSION
CONCLUSIONS
Afatinib led to longer PFS for patients with common EGFR mutations but not for those with rare mutations.
Identifiants
pubmed: 33813414
pii: 41/4/2059
doi: 10.21873/anticanres.14975
doi:
Substances chimiques
Afatinib
41UD74L59M
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Gefitinib
S65743JHBS
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2059-2065Informations de copyright
Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.